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Abstract
Socioeconomic status (SES) is defined as an individual’s social or economic standing, and is a measure of an individual’s or 
family’s social or economic position or rank in a social group. It is a composite of several measures including income, education, 
occupation, location of residence or housing. Studies have found a  lower SES has been linked to disproportionate access to 
health care in many diseases. There is emerging data in pulmonary diseases such as COPD, asthma, cystic fibrosis, pulmonary 
hypertension and other chronic respiratory conditions that allude to a similar observation noted in other chronic diseases. In the 
setting of COPD, SES has an inverse relationship with COPD prevalence, mortality, health utilization costs and HRQoL. Asthma 
and cystic fibrosis show an increased severity and hospitalizations in relationship to a lower SES. Similar observations were seen 
in sarcoidosis, PHTN and obstructive sleep apnea. There remains a limited data on non-CF bronchiectasis and interstitial lung 
diseases. Population SES may be gauged by various measures such as education, occupation, marital status but no value is more 
indicative than income. Currently guidelines and management algorithms do not factor the effect of SES in the disease process. 
Despite the great amount of data available, a standardized method must be created to include SES in the prognostic calculations 
and management of chronic pulmonary diseases.
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Introduction
Socioeconomic status (SES) is defined as an 
individual’s social or economic standing, and is 
a measure of an individual’s or family’s social or 
economic position or rank in a social group [1]. 
It is generally a composite of several measures 
including income, education, occupation (includ-
ing employment status), location of residence, 
housing (including home amenities), and may also 
include participation in social organizations [1–3]. 
Of all the measured demographics in healthcare 
today, SES may be the least reported but the most 
influential in a patients’ access to healthcare and 
clinical outcomes [4]. Globally healthcare cover-
age of every country’s individual populations is 
varied. In the United States which uses a combina-
tion of private and government sponsored health 
insurance, is in contrast to other countries which 
provide nationalized health coverage or none at 
all. However, despite efforts by many national 
governments to provide all members of society 
with access to healthcare, SES still has a profound 
effect on life expectancy and is still independently 
a risk factor for death as higher income is associ-
ated with greater longevity [5].
To the best of our knowledge studies across 
all fields of medicine have found a  lower SES 
Advances in Respiratory Medicine 2017, vol. 85, no. 2, pages 97–108 
98 www.journals.viamedica.pl
Table 1. Traditional measures of socioeconomic status [16]
Occupation
 — employment status (e.g., employed/unemployed/retired)
 — specific occupational group
 — aggregate occupation groups
 — blue-/white-collar workers
 — employment status
Education
 — years of education (aggregate)
 — highest educational level completed (i.e. High School,  
College, etc)
 — credentials earned (e.g., high-school diploma, Bachelors 
degree, graduate degrees)
Income
 — individual annual income
 — annual household income (aggregate)
 — family income
has been linked to disproportionate access to 
health care in many diseases, which leads to poor 
health outcomes [6]. A comprehensive review 
has found that there are increased risks relating 
to cardiovascular disease as well as access to in-
vasive cardiac procedures [7, 8], chronic kidney 
disease [9], diabetes mellitus [10] as well as in 
cancer survival [11]. There has been emerging 
data in various pulmonary diseases that alludes 
to a similar observation noted in other chronic 
diseases [12–15]. This review attempts to clearly 
outline the documented literature in regards 
of socioeconomic status and its relationship to 
common chronic respiratory diseases as well as 
highlight the role of SES is advanced lung disease 
as a barrier to access to health care. 
Socioeconomic status and its domains
Socioeconomic status (SES) is defined as an 
individual’s social and economic standing, and is 
a measure of an individual’s or family’s social or 
economic position or rank in a social group [1]. 
Traditional SES measures included occupation, 
education and income [16]. Each of these mea-
sures captures a distinct aspect of SES and may 
be correlated with other measures but are not 
easily interchangeable due to their finite nature. 
However, obtaining traditional measures of 
SES outlined in Table 1 may not always be feasible 
due to missed recordings, personal nature of ques-
tions, discrepancies in reporting, instructional 
review board constraints. In addition, as SES in 
epidemiological studies in often retrospective [16] 
relying on traditional measures may lead to a bevy 
of missing data. For this reason surrogates for 
the measurement of SES have been formulated. 
These forms of SES measures are referred to as 
contextual measurements. 
Contextual measures of SES focus on eco-
logical and geographic variables or may involve 
a combination of both. Contextual approaches to 
SES examine the social and economic conditions 
that affect all individuals who share a particular 
social environment or which they live in. Access 
to goods and services, the built environment, and 
social norms and other factors relevant to health 
are often determined by the community [17]. 
Researchers and public health officials have ac-
knowledged that the context in which one lives 
also contributes to health [18, 19]. Examples of 
contextual measures of SES may be at the neigh-
borhood level and include ZIP codes, census 
tracts, census block groups or census blocks. It 
may also include other geographic areas such as 
counties, regions and states [16].
The accuracy of these measures in terms of 
SES within the census tract, ZIP code, county 
or other community areas can vary widely de-
pending upon the amount of time that has passed 
since these data were collected and the dynam-
ic nature of the geographic area of interest (e.g., 
patterns of movement into and out of the area, 
gentrification, changes in the industry, unem-
ployment rates and so forth). In addition, racial/ 
/ethnic differences an underreporting in census data’ 
suggest that the reliability may not always be there. 
Underreporting may occur in special populations 
such as migrants and the undocumented popu-
lations who are not accounted for in census and 
epidemiological studies. A proposed relationship 
between SES and healthcare delivery in the setting 
of chronic respiratory disease has been shown in 
Figure 1.
Chronic obstructive pulmonary disease (COPD)
Chronic obstructive pulmonary disease 
(COPD) is a chronic disease characterized by poor 
outward airflow from the lungs. Tobacco smoking 
is most commonly implemented in the pathogen-
esis. As a disease with a reversible component, 
SES plays an important role as access to care may 
reverse or stop progression of the disease. COPD 
outcome disparities have been attributed to many 
factors associated with SES such as smoking, oc-
cupation, environmental pollution and develop-
mental factors such as childhood infections and 
asthma [20]. Often environmental factors are also 
associated with SES living conditions. Extensive 
research has been conducted to determine if SES 
affects the status and risk of developing COPD and 
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Figure 1. Proposed relationship between socioeconomic status (SES) and healthcare delivery in the setting of chronic respiratory disease
mortality [12]. Studies analyzing SES and COPD 
have been outlined in Table 2.
Chronic obstructive pulmonary disease is one 
of the most common chronic respiratory disorders 
and multiple studies have found its prevalence to be 
higher in the lower SES population. In a preliminary 
study of NHANES surveys, Whittemore et al. [30]
reported a significant inverse relationship between 
income and COPD for both men and women. Various 
authors have found that household income was an 
important determinant of the prevalence of COPD 
and that the prevalence of COPD was significantly 
higher among respondents from lower income 
households for both men and women [21, 24, 26]. 
As demonstrated, SES plays a pivotal role 
in severity of COPD. There may be many factors 
that contribute to this phenomenon. COPD is 
strongly linked to the use of tobacco. It has been 
found that smoking prevalence continues to be 
higher among socially disadvantaged groups [31] 
and that smoking itself may in fact be a better 
predictor of long term survival than SES [32]. 
Taking this into consideration it is also plausible 
that smoking cessation options might not be as 
readable available to this population due to cost. 
It has been observed by Broms et al. [33] that 
a higher SES as measured by education and social 
class was associated with higher rates of smoking 
cessation. The relationship of tobacco use and 
cessation plays a key role in inverse relationships 
seen between SES and COPD.
In addition to disease severity measures it 
has been found that SES plays an integral role 
in mortality. In a study by Gershon et al. [28], 
based purely on household income in a single 
payer healthcare system, it was found that there 
was statistically significant difference in the mor-
tality difference between the lowest and highest 
income quintiles. Mortality increased from 67 
per 10,000 individuals in 1996–1997 to 86 per 
10,000 individuals representing a 28% relative 
increase. It was also observed that mortality in 
people with COPD has decreased faster in people 
with the highest compared with the lowest SES, 
causing increased disparity between rich and 
poor. Further study and strategies are needed to 
explore and address factors responsible for this 
increasing disparity in the COPD population [28]. 
Lewis et al. [25] analyzed traditional markers of 
SES as well as other contextual measures and 
determined that a lower household income and 
educational status were independent risk factors 
for mortality due to COPD. 
Most recently a study by Cho et al. [29], the 
first prospective study to demonstrate that indi-
vidual and neighbor socioeconomic status play 
a  role in all-cause mortality of COPD patients. 
Compared to high-income patients from advan-
taged neighborhoods, the adjusted hazard ratio 
for middle-income COPD patients who lived in 
advantaged and disadvantaged neighborhoods 
was 1.22 (95% CI, 1.03–1.43) and 1.36 (95% CI, 
Advances in Respiratory Medicine 2017, vol. 85, no. 2, pages 97–108 
100 www.journals.viamedica.pl
Table 2. Selected studies demonstrating relation of SES and COPD prevalence and mortality
Study Year Location N SES Measure (Source of SES Info) SES Findings
Chen et al. [21] 2000 Canada 3654 Household Income 
(National Population Health Survey)
↑ COPD prevalence  
in lower SES
Welle et al. [22] 2004 Norway 1512 Education
(Patient Reported Occupation
↓ COPD prevalence  
with ↑ SES 
Steenland et al. [23] 2004 United 
States
Employed  
individuals  
from 27 states
Occupation
(Nam-Powers scores for occupation)
↑ Rate of COPD  
Mortality in ↓ SES 
Schikowski et al. [24] 2008 Germany 1172 Education
(Self-administered standardized questionnaire)
↑ COPD prevalence  
with ↓ SES 
Lewis et al. [25] 2009 United 
States
189924 Household Income
Education Level
Health Insurance
Marital Status
(National Longitudinal Mortality Study)
↑ Mortality risk in lower 
SES based on Income 
and Education
Kanervisto et al. [26] 2010 Finland 8028 Household Income 
Education Level
(Health 2000 Survey)
↑ COPD risk in lower 
SES
Yin et al. [27] 2011 China 49363 Household Income 
Education Level 
(China Chronic Disease Risk Factor Surveillance 
in 2007)
↑ COPD prevalence in 
lower SES
Gershon et al. [28] 2014 Canada 428046
807996
Household Income
(Canadian Census postal code)
Mortality rate ↓ faster in 
higher SES as compared 
to lower SES
Cho et al. [29] 2016 Korea 9275 Household Income
Neighborhood Deprivation
(Monthly Insurance Premium, 2005 Korean Cen-
sus, Carstairs Index)
↑ Mortality in lower 
SES individually and by 
neighborhood
SES — socioeconomic status;  COPD — chronic obstructive pulmonary disease
1.15–1.60), respectively. For low-income patients, 
the adjusted HR for patients who lived in dis-
advantaged neighborhoods was higher than for 
patients who lived in advantaged neighborhoods 
(HR, 1.43; 95% CI, 1.17–1.74 vs. HR, 1.36; 95% 
CI, 1.11–1.66). 
As it has been demonstrated by various stud-
ies that prevalence as well as mortality is related 
to variations in SES, another interesting aspect 
of the disease is the health utilization costs. As 
COPD is often complicated with exacerbations 
requiring hospitalizations, assumption would 
suggest that SES plays a role in hospitalizations 
and the ultimate cost of healthcare. A study on 
the geriatric population determined that COPD 
hospitalization rate was inversely related to in-
come in both males and females and that higher 
income was associated with lower co-morbidity 
[34]. A study in Canada, which utilizes a single 
payer system, as in Poland, it was observed that 
hospital admission rates for COPD patients in 
a lower SES group were about three-fold higher, 
than those in the high SES group. This alludes 
to the fact that socioeconomic barriers exist in 
access to healthcare or therapy. 
Furthermore all chronic disease have a neg-
ative impact on health related quality of life 
(HRQoL) which is defined as by the Center for 
Disease Control as an assessment of how an in-
dividual’s well-being is being affected over time 
by a disease, disability, or disorder. A study from 
Spain by Miravitlles et al. [35] determined that 
there was a gradient of impairment in HRQoL 
according to the educational level, as well as in 
more unskilled workers. HRQoL was measured 
using EQ-5D and AQ20 questionnaires that as-
sessed patient reported perception of “current 
health”, the five dimensions of mobility, self-care, 
usual activities, pain/discomfort, anxiety/depres-
sion and finally respiratory HRQoL in COPD. 
There was a gradient of impairment in HRQoL 
according to the educational level, with signifi-
cantly worse scores for the EQ-5D and the AQ20 
for medium and low educational levels compared 
with high education. Similarly, HRQoL was also 
significantly impaired in more unskilled workers 
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Table 3. Selected studies demonstrating relation of SES and asthma
Study Year Location N SES Measure (Source of SES Info) Relationship to SES
Mielck et al. [39] 1996 Germany 4434 Education Level (Parents)
(Modified American Thoracic Society Questionnaire)
↑ prevalence of severe  
asthma in lower SES
Eagan et al. [40] 2004 Norway 2819 Education Level
(Hordaland County Cohort Study)
↑ risk in developing asthma 
in lower SES
Basagana et al. [41] 2004 Inter-
national
10971 Occupation
Education Level
(European Community Respiratory
Health Survey)
↑ prevalence of asthma 
regardless of atopy in lower 
SES
Ellison-Loschmann 
et al. [42]
2007 Inter-
national
9023 Occupation
Education Level
(European Community Respiratory
Health Survey)
↑ prevalence of asthma with 
no atopy and ↑ traditional 
asthma prevalence and in-
cidence in lower SES
Ungar et al. [43] 2011 Canada 490 Family Income Adequacy
(National Population Health Survey)
↑ exacerbations in lower 
SES families
SES — socioeconomic status
than skilled workers. These differences remained 
significant after controlling for covariates [35].
In the setting of COPD the literature depicts 
that when all variables are controlled, SES has 
an inverse relationship with COPD prevalence, 
mortality, health utilization costs and HRQoL. 
Prevalence of disease is strongly associated with 
tobacco use that is more common in socially dis-
advantaged populations [36]. Despite controlling 
for cofounding factors there may be social aspects 
of the disease that may not be accountable for that 
influence mortality. In population with a lower 
socioeconomic status, access to healthcare in 
an issue that may lead to increased morbidity 
and mortality. Not only is access to health care 
a plausible reason for higher mortality rate in 
the socially disadvantaged, access to smoking 
cessation education and medication may also 
play a role. Psychosocial aspects of disease, often 
less explored, have also been influenced by SES. 
Lower social classes have an inherent tendency 
to experience a lower HRQoL [37] but in the set-
ting of COPD, a chronic progressive debilitating 
dyspneic disease, the role of SES in relation to 
HRQoL may be more profound or easy to detect.
Asthma 
Asthma is a chronic inflammatory condition 
of the airways with many etiologies that has an 
ill-defined relationship with SES. Comprehensive 
studies have concluded that a  lower socioeco-
nomic position is in fact associated with asthma 
severity and prevalence [38]. Asthma is often 
addressed in the pediatric and young adult pop-
ulation so parent and guardian SES is assessed as 
a surrogate for the patient. The studies that have 
looked at asthma in relation to SES have been 
outlined in Table 3.
A study that analyzed populations from Eu-
rope, USA, Australia and New Zealand surveying 
patients using the European Community Respi-
ratory Health Survey determined that prevalence 
and incidence of asthma with no atopy were 
associated with low educational level. Subjects 
in the low occupational class (incident risk ratio 
(IRR) 1.4; 95%CI 1.2–1.7) and education group 
(IRR 1.3; 95% CI 1.1–1.6) had higher mean asthma 
scores than those in higher socioeconomic groups 
and that lower socioeconomic groups tended to 
have a higher prevalence and incidence of asth-
ma, particularly higher mean asthma scores [42]. 
In a study by Basagana et al. [41] using the same 
survey found similar results, that asthma preva-
lence was higher in lower socioeconomic groups, 
whether defined by educational level or social 
class regardless of atopic status. 
In addition to epidemiological findings it 
has also been found that asthma disease severity 
is linked to SES. A study by Mielck et al. [39] 
examining the severity of asthma in children 
looks at the SES of parents as assessed by their 
highest education level determined. Prevalence 
of severe asthma was found to be significantly 
higher in the low as compared with the high 
socioeconomic group and was not explained by 
established risk factors. In a study by Eagan et 
al. [40] it was determined that a lower education 
level, which may be a used as a marker of SES, 
was associated with a higher risk of developing 
asthma. The adjusted OR (95% CI) for the inci-
dence of asthma was 2.1 (1.01, 4.4) in subjects 
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Table 4. Socioeconomic studies in cystic fibrosis
Study Year Location n SES Measure (Source of SES Info) Relationship to SES
Britton et al. [44] 1989 United Kingdom Variable Occupation (non-manual  
vs. manual professions)
(Office of Population Censuses and Surveys)
↑ age of death in non 
manual occupations 
(higher SES)
Schechter et al. [14] 1998 United States 261 Insurance type (Medicaid vs. Non-Medicaid)
(The National Cystic Fibrosis Foundation Pa-
tient Registry (NCFPR))
↑ Hospitalizations and 
hospital days in lower 
SES
↓ FEV1 in lower SES
Schechter et al. [45] 2001 United States 20390 Insurance type (Medicaid vs. Non-Medicaid)
(NCFPR)
↑ Risk of death and 
hospitalization in lower 
SES
O’Connor et al. [46] 2003 United States 23817 Zip Coded Based Median Household income 
(1990 U.S. Census Data)
↑ incidence rate of 
death in lower SES zip 
codes
↓ FEV1 in lower SES
Quittner et al. [47] 2010 United States 6577 Insurance type (Medicaid vs. Non-Medicaid)
(Epidemiologic Study of CF)
↓ FEV1 in lower SES
↓ HRQOL Score in lower 
SES
Stephenson et al. 
[48]
2011 Canada 1174 Postal code based neighborhood income  
(Statistics Canada census data)
No SES disparities  
in hospitalization  
in adult or pediatrics
SES — socioeconomic status; FEV1 — forced expiratory volume in one second
with a primary educational level, and 2.0 (1.04, 
3.6) in subjects with a  secondary educational 
level as compared to subjects with a university 
educational level. These were the findings after 
adjustment for sex, age, hay fever, smoking, and 
occupational exposure.
In an ideal situation the health disparities 
that have been demonstrated in a multi-payer 
health care system should, in theory not be seen 
in a single payer healthcare systems. However 
in a study by Ungar et al. [43] in the Canadian 
universal healthcare system found that families 
with a medium or high income adequacy had 28% 
fewer exacerbations as compare to those with a low 
income adequacy. The study from Ungar et al. [43], 
in a single payer system, depicted that despite 
universal healthcare coverage, asthma may not be 
adequately managed in the socially disadvantaged.
Cystic fibrosis
Cystic fibrosis (CF) is a unique situation in 
when patients are diagnosed from an early age. 
There is also extensive follow up that provides 
a good data set and the possibility to conduct 
comprehensive longitudinal studies. This is 
a genetic driven disease; however SES plays an 
important role as a modifiable factor influencing 
management, morbidity and outcomes. CF pa-
tients require extensive follow up and are prone to 
lingering infections, which hamper their health. 
Studies examining the role of SES in CF have been 
outlined in Table 4. Early studies to examine the 
social aspect of CF included a study by Britton 
that showed that there was a trend for a higher age 
of death in non-manual jobs for fathers or spous-
es of patients as compared to manual jobs. For 
those who worked themselves, it was found that 
manual workers had a better prognosis than those 
non-manual workers [44]. This preliminary study 
started a dialogue on the possible effects of SES 
on CF disease. One of the initial studies looking 
at CF disease severity and its relationship to SES 
was a study by Schechter and Margolis that found 
Medicaid patients, representing a lower SES, have 
worse lung function and required more treatment 
for pulmonary exacerbations than their more 
advantaged counterparts [14]. This difference ap-
peared to begin early in life, did not increase with 
age, and was not explained by inadequate access 
to outpatient specialty care or delayed diagnosis. 
The study also offered other explanations to their 
findings such as inadequate access to primary 
care, poor adherence to prescribed regimens, and 
possible greater exposure to pollutants (e.g., en-
vironmental tobacco smoke) are speculative [14]. 
In a  follow up study by Schechter et al. [45] it 
was found that the adjusted risk of death was 
3.65 times higher for Medicaid patients than for 
those not receiving Medicaid and those Medicaid 
patients were 1.60 times more likely to require 
treatment for a pulmonary exacerbation.
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Not only has socioeconomic status been im-
plemented in disease severity but it has also been 
shown to affect mortality. In a study by O’Connor 
et al. [46] there was a strong association between 
the median household income and the mortality 
rate before and after adjusting for a variety of 
patient and disease characteristics. In addition 
patients living in lower median household income 
area demonstrated lower pulmonary function 
and body weight than did those living in higher 
income areas. 
There is a unique aspect of psychosocial 
medicine in regard to CF. It is a disease that often 
affects children and is associated a high level 
of burden with an emphasis of health related 
quality of life (HRQoL). SES, in general affects 
quality of life, as it is often measure by income, 
education, family size, occupation, etc. A study 
by Quittner et al. [47] looked at the impact of SES 
on the quality of life of CF patients. In general it 
was found that patients with Medicaid, a marker 
for low SES, all aged patients had worse lung 
function and worse patient reported outcomes 
according to the Cystic Fibrosis Questionnaire 
Revised (CFQ-R). 
In refractory CF disease, lung transplantation 
remains a treatment option for those patients in 
end stage lung disease. Criteria for lung trans-
plantation in the CF population are based on 
many factors including guidelines set forth by 
the International Society for Heart and Lung 
Transplantation [49]. Socioeconomic status as 
measured by zip code median house hold income, 
education level as well as Medicaid insurance 
have all independently associated with not being 
accepted for lung transplantation despite meet-
ing all the criteria [50]. In fact a study by Ramos 
et al. [51] has found that a low SES is a predictor 
of non-referral for lung transplantation. This has 
to be examined further as a study by Stephenson 
et al. [48] showed that despite varying neighbor-
hood SES there were no disparities in hospital-
ization rates in a  large Canadian pediatric and 
adult CF cohort. 
Cystic fibrosis, due to its early diagnosis in 
a pediatric population provides an ideal situation 
for comprehensive follow up and longitudinal 
studies. Though SES does not affect incidence, 
as this is a genetic disease, it is evident overall 
lung function is lower in lower SES groups. It 
has also been noted that that risk of hospitaliza-
tions and duration of hospital stays are longer in 
a lower SES. This observation may allude to the 
fact that there may be social aspects that prevent 
proper follow up or access to medications. The 
continuality of irregular follow up is the increased 
risk of death, which has been noted in multiple 
studies. There is evidence that a  lower SES, as 
measured by income as well as type of insurance 
is an independent risk factor for death in the set-
ting of CF. Furthermore as this is a progressively 
worsening disease the definitive treatment is 
lung transplant. Multiple studies have shown 
that definitive treatment may be hindered due to 
a  lower SES. Despite the uniformity of data on 
the relationship of SES and CF, there still seems 
to be a barrier to adequate care. 
Sarcoidosis
Sarcoidosis is a granulomatous disorder of 
unknown etiology that may affect any organ in the 
body but most often affects the lungs, lymph nodes, 
skin, and eyes, respectively. The disease exhibits 
two distinct clinical courses: an acute course 
that usually resolves or stabilizes within 2 years, 
and a chronic course that is progressive and may 
lead to severe organ dysfunction and death [52]. 
Sarcoidosis severity has shown a  geographic 
variation as well as more advanced disease in mu-
nicipal hospitals versus private hospitals [53, 54]. 
These observations in some part have been at-
tributed to SES. Studies analyzing sarcoidosis in 
relationship to SES have been outlines in Table 5. 
In the first study to look at disease severity in 
correlation with SES was Rabin et al. [55]. It was 
observed that a lower SES and no or public in-
surance were associated with worse health status 
and more severe dyspnea. More advanced radio-
graphic stage was associated with lower income, 
and forced vital capacity impairment with less 
education [55]. Patients who had incomes less 
than $20,000 a year were 3.5 times more likely 
to have Stage 3–4 disease than patients with an 
income greater than $50,000 a year. Patients with 
the highest incomes were more likely (36% vs. 
7%) to have Stage 1 disease than patients with 
the lowest incomes. Physical and social activity 
limitations due to physical and emotional dis-
ability were related to no or public insurance 
and lower income, but not education. Sarcoidosis 
severity is associated with socioeconomic status 
and insurance indicators; no or public insurance 
and low income are associated with functional 
limitations [55].
To confirm the previous study Rabin et al. [56] 
set out to determine sarcoidosis disease severity 
at first presentation. The results of the study 
showed that lower income, the absence of pri-
vate or Medicare health insurance were associ-
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Table 5. Socioeconomic studies in sarcoidosis
Study Year Location N SES Measure (Source of SES Info) Relationship to SES
Yeager et al. [53] 1999 United States 91 Use of Private Hospital vs. Municipal  
Hospital
Insurance Status
↑ disease stage and ↓ lung 
function in lower SES
Rabin et al. [55] 2001 United States 110 Household Income
Education Level
Insurance Type (Sarcoidosis Telephone 
Survey Form; Nation Health Interview 
Survey)
↓ SES is associated with 
more severe disease and 
functional limitation
Rabin et al. [56] 2004 United States 696 Income
Education
Insurance Type (ACCESS Questionnaire [57]
↓ SES is associated more se-
vere disease at presentation
SES — socioeconomic status
ated with sarcoidosis severity at presentation, as 
were race, sex, and age. African Americans were 
more likely to have severe disease by objective 
measures, while women were more likely than 
males to report subjective measures of severity. 
Older individuals were more likely to have se-
vere disease by both measures. In conclusion, it 
was found that low income and other financial 
barriers to care are significantly associated with 
Sarcoidosis severity at presentation even after 
adjusting for demographic characteristics of race, 
sex, and age [56]. 
Advanced lung diseases
Pulmonary hypertension
Pulmonary hypertension (PHTN) is a rare and 
devastating disease characterized by progressive 
increases in pulmonary arterial pressure and pul-
monary vascular resistance that eventually leads 
to right ventricular failure and death [58, 59]. 
It may due to various etiologies such as left heart 
disease; parenchymal lung disease, chronic 
thromboembolic disease, hematologic disorders 
or it may be idiopathic in nature though the clini-
cal picture of these patients is similar [60]. Of the 
various groups of PHTN, pulmonary arterial hy-
pertension (PAH), WHO Group I PAH is now phar-
macologically treatable with many options [61]. 
For this reason, early diagnosis is critical for pre-
venting disease progression. Unfortunately, the 
diagnosis of PAH is often difficult to make and 
can require multiple physician visits and referral 
to a medical specialist (i.e., cardiologist, pulmon-
ologist) with specific training in pulmonary vas-
cular disease. Despite the emergence of effective 
therapy, PAH is commonly at an advanced stage 
when recognized. Studies have shown that there 
is a delay in the recognition of PAH. One in five 
patients in the REVEAL registry who were even-
tually diagnosed with PAH reported symptoms for 
more than 2 years before their disease was recog-
nized. It was also noted that younger individuals 
and patients with histories of common dyspneic 
disorders were more likely to experience delayed 
PAH recognition [62].
Though the role of socioeconomic status SES 
has not been as exhaustively explored in PHTN 
as the aforementioned conditions, studies have 
shown that all across all groups of PHTN, SES is 
associated with a more severe disease at presen-
tation [15]. A study by Talwar et al. [15] on 228 
PHTN patients showed that as median income 
decreased, the WHO FC at presentation increased, 
signifying higher disease severity. A similar anal-
ysis was done of WHO Group I PAH patients and 
there was again a negative relationship between 
income and initial FC. 
The reasoning for this observation seems to be 
varied. Despite the development of numerous ther-
apies over the past 20 years, the delay to diagnosis 
has not decreased over the past 3 decades [63, 64]. 
One possible reason for the delayed diagnosis and 
more severe disease at presentation for lower SES 
individuals may be due to access to advanced di-
agnostic procedures. A Right heart catheterization 
(RHC) is needed to make the diagnosis of PAH and 
distinguish it from other forms of PHTN. RHC 
is a costly, hospital-based, invasive procedure 
and may not be readily accessible to people with 
a lower SES [8]. SES not only plays a role in the 
diagnosis and treatment of the disease, it also 
has a profound effect on the clinical outcome of 
these patients. In a study by Wu et al. [65] it was 
found that a lower SES was strongly associated 
with a higher risk of death in PAH independent 
of other clinical characteristics, hemodynamics, 
and treatment.
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Interstitial lung disease
Interstitial lung disease (ILD) is a group dis-
ease of the interstitium. It may be due to inhaled 
substances, drug induced, infection related, 
associated with connective tissue disease (CTD) 
or idiopathic in nature [66]. Currently the au-
thors are not aware of any other publications in 
peer-reviewed journals that examine the role of 
SES and idiopathic interstitial lung disease. The 
majority of mention of SES pertains to the role 
of SES in CTD related ILD. The most common 
CTD associated with associated ILD are sclero-
derma, polymyositis, dermatomyositis, systemic 
lupus erythematosus and rheumatoid arthritis. 
In a study by Koduri et al. [67] it was noted that 
in patients with rheumatoid arthritis associated 
ILD, Risk of death was almost double in patients 
with low socio-economic status. 
Other chronic respiratory diseases
Obstructive sleep apnea
Obstructive sleep apnea (OSA) is a condition 
that often requires subspecialist care and the use 
of durable medical equipment (DMEs). Diagnosis 
and management options are attained after costly 
polysomnography and continuous positive airway 
pressure (CPAP) testing. From this information 
alone it is plausible that SES may play an im-
portant role in OSA. There is not much in the 
literature about OSA and SES. 
The main study, which looks at OSA in 
respect to SES, was a study by Greenberg et al. 
[68] In this study severity of OSA was assessed 
at a voluntary hospital serving primarily middle 
class individuals with health insurance and 
a minority serving hospital treating primarily 
uninsured lower SES individuals. It was found 
that despite similar age and apnea hypopnea in-
dex, that the minority serving hospital patients 
had a greater body mass index, higher daytime 
systemic blood pressure, more comorbid medical 
conditions, and a lower minimum sleep SaO2 than 
the voluntary hospitals patients. It was also noted 
that systemic hypertension, diabetes mellitus, 
asthma, and congestive heart failure were more 
prevalent in the patient group from the minority 
serving hospital and that forty two percent of 
these patients diagnosed with OSA failed to fol-
low up for treatment as compared with 7% in the 
voluntary hospital group. These findings suggest 
that OSA may be an important factor contributing 
to socioeconomic-based differences in morbidity 
and mortality. 
OSA is primarily treated with the use of CPAP 
therapy. A lower socioeconomic status has also 
been noted to be a risk factor for CPAP acceptance. 
In a study by Bakker et al. [69] it was determined 
that patients with low SES are less receptive to 
CPAP treatment than groups with higher SES and 
that patients who indicate a higher level of social 
economic deprivation adhered less to CPAP ther-
apy than those who have a better social economic 
situation. There is still much more research that 
needs to be conducted to solidify the role of SES 
in OSA diagnosis, severity and management but 
as per preliminary studies it appears as if SES 
does play a role in the disease severity and man-
agement strategies (Table 6). 
Non cystic fibrosis bronchiectasis
Bronchiectasis is often dealt with in a pedi-
atric population especially in the CF population. 
We have addressed the relationship of SES in 
CF and have observed that it is more prevalent, 
severe, and detrimental to HRQoL in a  lower 
SES, however not much is known on the adult 
population and Non-CF related bronchiectasis in 
conditions such as tuberculosis, HIV, mycobacte-
rium avium infection. There is not much in the 
literature regarding adult bronchiectasis and SES. 
In one study by Roberts et al. [70] it was found 
that exacerbations of bronchiectasis were more 
common in patients who are socioeconomically 
deprived. Exacerbations in the setting of bronchi-
ectasis often warranted hospital admission and is 
associated with high readmission and mortality 
rates [70]. The paucity of data may be in part 
Table 6. Socioeconomic studies in obstructive sleep apnea (OSA)
Study Year Location N SES Measure (Source of SES Info) Relationship to SES
Greenberg et al. [68] 2004 United States 303 Voluntary vs. Minority Serving Hospital ↑ OSA with comorbi-
dities and failure to fol-
low up in lower SES
Bakker et al. [69] 2011 New Zealand 126 Individual Income
Education
Employment
↓ compliance with CPAP 
therapy in lower SES
SES — socioeconomic status; CPAP — continuous positive airway pressure
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due to lack of recording socio-epidemiological 
measures in non-CF bronchiectasis, though there 
might be a  relationship of individual disease 
processes and SES.
Conclusion
Socioeconomic status, regardless of how it is 
assessed continues to be an important measure that 
correlates to access to healthcare. In the strata of 
common chronic respiratory diseases we have seen 
many advances in the way of pharmacotherapy, 
diagnostic testing and management guidelines. 
However SES remains to be the most influential 
barrier to access to healthcare. SES has been asso-
ciated with incidence, prevalence and has shown 
its influences on disease severity and clinical out-
comes. The greatest amount of data regarding SES 
exists for the diseases that are considered the most 
“manageable” by clinicians i.e. COPD and asthma. 
An outlier to this is the data that has been collected 
by the CF community that continues to research 
their population to learn all social determinants 
of the disease. However there remains a paucity of 
data on advanced lung diseases such as pulmonary 
hypertension and interstitial lung disease. 
Despite the great amount of data available, 
a standardized method must be created to include 
SES in the prognostic calculations of disease. Cur-
rently guidelines and management algorithms do 
not factor the effect of SES in the disease process. 
However from the emerging data is clearly evident 
that SES plays an important role in the risks, 
morbidity, mortality, health related quality of life 
and most importantly clinical outcomes. An effort 
need to be made by governing bodies to account 
for the impact SES has in the clinical outcomes 
in common respiratory diseases. In advanced lung 
diseases such as pulmonary hypertension and 
interstitial lung disease a greater focus needs to 
be placed on SES as it might be a modifiable risk 
factor affecting access to healthcare.
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